Dupixent and Narrowband UVB for Atopic Dermatitis

Description

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Conditions

Atopic Dermatitis

Talk to us

Study Overview

On this page

Study Details

Study overview

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination With Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis

Dupixent and Narrowband UVB for Atopic Dermatitis

Condition
Atopic Dermatitis
Intervention / Treatment

-

Contacts and Locations

East Windsor

Eczema Treatment Center of New Jersey, East Windsor, New Jersey, United States, 08520

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Male or female adult ≥ 18 years of age;
  • * Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:
  • * EASI score of 16 or greater,
  • * IGA score of 3 or greater
  • * BSA of 10% or greater,
  • * Subjects with previous exposure to dupilumab.
  • * Known or suspected hypersensitivity to dupilumab or any of its excipients.
  • * History of photosensitivity.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Psoriasis Treatment Center of Central New Jersey,

Study Record Dates

2024-12-15